← Human Trials & Peer-Reviewed Studies
Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers
Plain-language guide to PMID 15860969 (2005): double-blind randomized controlled trial study of BNP (Nesiritide) in 489 patients.
Key Facts
- PMID
- 15860969
- Journal
- Congestive heart failure (Greenwich, Conn.)
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Abraham WT et al. (3 authors)
- DOI
- 10.1111/j.1527-5299.2005.03792.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.
The use of beta blockers in congestive heart failure presents a therapeutic challenge for patients with acute episodes of decompensation.
The Vasodilation in the Management of Acute CHF trial was a multicenter, randomized, controlled evaluation of nesiritide in 489 hospitalized patients with decompensated congestive heart failure.
Who Took Part
The abstract describes 489 patients taking part.
The age groups tagged for this paper are middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.
Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.
Neither the patients nor the staff measuring them knew who was on BNP (Nesiritide), so expectations could not easily colour the readings.
Some patients received a placebo instead of BNP (Nesiritide), giving a reference point.
Running at several centres spread the BNP (Nesiritide) study over different clinics and patient groups.
What Was Measured
The Vasodilation in the Management of Acute CHF trial was a multicenter, randomized, controlled evaluation of nesiritide in 489 hospitalized patients with decompensated congestive heart failure.
Primary end points included pulmonary capillary wedge pressure and dyspnea evaluation at 3 hours.
The subject headings attached to it are Adrenergic beta-Antagonists, Heart Failure, Hemodynamics, Natriuretic Agents, Natriuretic Peptide, Brain, Nitroglycerin and Pulmonary Wedge Pressure.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of BNP (Nesiritide) in 489 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2005 (Congestive heart failure (Greenwich, Conn.)), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.